Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice

Cancer Lett. 1999 Apr 1;137(2):183-91. doi: 10.1016/s0304-3835(98)00353-x.

Abstract

C57BL/10 mice transgenic for HLA-A2 were immunized with either a full-length DNA-construct of the tumor suppressor p53 or with a minigene encoding the p53-derived immunodominant peptide p53(264)LLGRNSFEV272 (L9V). Vaccination with the full-length p53 construct induced potent cytotoxic activity of splenocytes against L9V-pulsed target cells after in vivo re-stimulation. Vaccination with the L9V-encoding minigene likewise induced specific anti-L9V cytotoxicity in vitro. Subsequent experiments revealed that peptide-pulsed dendritic cells were the most efficient cell types for in vitro re-stimulation. In concordance with this, immunization with L9V-pulsed dendritic cells also induced a potent and specific anti-L9V cytotoxic response in vitro. These data show that HLA-A2/peptide-specific cytotoxic immunity can be generated in vivo against the same immunodominant epitope by immunizing either with full-length DNA or with a DNA minigene encoding the immunodominant peptide epitope.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • COS Cells
  • Cytotoxicity Tests, Immunologic
  • Dendritic Cells / cytology
  • Dendritic Cells / immunology
  • Gene Expression / immunology
  • HLA-A2 Antigen / genetics
  • HLA-A2 Antigen / metabolism*
  • Humans
  • Immunity, Cellular / genetics
  • Immunodominant Epitopes*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Peptide Fragments / genetics
  • Peptide Fragments / immunology
  • T-Lymphocytes, Cytotoxic / immunology
  • Transfection
  • Tumor Suppressor Protein p53 / genetics*
  • Tumor Suppressor Protein p53 / immunology*
  • Tumor Suppressor Protein p53 / metabolism
  • Vaccines, DNA / immunology*

Substances

  • HLA-A2 Antigen
  • Immunodominant Epitopes
  • Peptide Fragments
  • Tumor Suppressor Protein p53
  • Vaccines, DNA